OMERS Life Sciences’ $200 Million Acquisition of Portion of Global Royalties on MAVYRE

Martina Bellini
Tagged:

Ballard Spahr represented OMERS Life Sciences on the deal. Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Martina Bellini

Author: Martina Bellini

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here